Construction and immunological evaluation of hepatitis B virus core virus-like particles containing multiple antigenic peptides of respiratory syncytial virus

2021 ◽  
pp. 198410
Author(s):  
Lei Lei ◽  
Huan Qin ◽  
Jin Luo ◽  
Yiluo Tan ◽  
Jie Yang ◽  
...  
2020 ◽  
Vol 94 (13) ◽  
Author(s):  
Jie Yang ◽  
Chen Ma ◽  
Yu Zhao ◽  
Anjing Fan ◽  
Xiufen Zou ◽  
...  

ABSTRACT Respiratory syncytial virus (RSV) is the most important cause of lower respiratory tract infection in infants and young children. The vaccine-enhanced disease (VED) has greatly hindered the development of an RSV vaccine. Currently, there are no licensed vaccines for RSV. In this study, immunization of mice with hepatitis B virus core particles containing a conserved region of the G protein (HBc-tG) combined with interleukin-35 (IL-35) elicited a Th1-biased response and a high frequency of regulatory T (Treg) cells and increased the levels of IL-10, transforming growth factor β, and IL-35 production. Importantly, immunization with HBc-tG together with IL-35 protected mice against RSV infection without vaccine-enhanced immunopathology. To explore the mechanism of how IL-35 reduces lung inflammation at the gene expression level, transcription profiles were obtained from lung tissues of immunized mice after RSV infection by the Illumina sequencing technique and further analyzed by a systems biology method. In total, 2,644 differentially expressed genes (DEGs) were identified. Twelve high-influence modules (HIMs) were selected from these DEGs on the basis of the protein-protein interaction network. A detailed analysis of HIM10, involved in the immune response network, revealed that Il10 plays a key role in regulating the host response. The selected DEGs were consistently confirmed by quantitative real-time PCR (qRT-PCR). Our results demonstrate that IL-35 inhibits vaccine-enhanced immunopathology after RSV infection and has potential for development in novel therapeutic and prophylactic strategies. IMPORTANCE In the past few decades, respiratory syncytial virus (RSV) has still been a major health concern worldwide. The vaccine-enhance disease (VED) has hindered RSV vaccine development. A truncated hepatitis B virus core protein vaccine containing the conserved region (amino acids 144 to 204) of the RSV G protein (HBc-tG) had previously been shown to induce effective immune responses and confer protection against RSV infection in mice but to also lead to VED. In this study, we investigated the effect of IL-35 on the host response and immunopathology following RSV infection in vaccinated mice. Our results indicate that HBc-tG together with IL-35 elicited a balanced immune response and protected mice against RSV infection without vaccine-enhanced immunopathology. Applying a systems biology method, we identified Il10 to be the key regulator in reducing the excessive lung inflammation. Our study provides new insight into the function of IL-35 and its regulatory mechanism of VED at the network level.


2020 ◽  
Vol 12 (48) ◽  
pp. 53682-53690
Author(s):  
Keman Cheng ◽  
Tao Du ◽  
Yao Li ◽  
Yingqiu Qi ◽  
Huan Min ◽  
...  

2004 ◽  
Vol 72 (11) ◽  
pp. 6519-6527 ◽  
Author(s):  
Elizabeth H. Nardin ◽  
Giane A. Oliveira ◽  
J. Mauricio Calvo-Calle ◽  
Kristiane Wetzel ◽  
Carolin Maier ◽  
...  

ABSTRACT We report the first phase I trial to assess the safety and immunogenicity of a malaria vaccine candidate, ICC-1132 (Malarivax), composed of a modified hepatitis B virus core protein (HBc) containing minimal epitopes of the Plasmodium falciparum circumsporozoite (CS) protein. When expressed in Escherichia coli, the recombinant ICC-1132 protein forms virus-like particles that were found to be highly immunogenic in preclinical studies of mice and monkeys. Twenty healthy adult volunteers received a 20- or a 50-μg dose of alum-adsorbed ICC-1132 administered intramuscularly at 0, 2, and 6 months. The majority of volunteers in the group receiving the 50-μg dose developed antibodies to CS repeats as well as to HBc. Malaria-specific T cells that secreted gamma interferon were also detected after a single immunization with ICC-1132-alum. These studies support ICC-1132 as a promising malaria vaccine candidate for further clinical testing using more-potent adjuvant formulations and confirm the potential of modified HBc virus-like particles as a delivery platform for vaccines against other human pathogens.


2015 ◽  
Vol 189 (2) ◽  
pp. 73-80 ◽  
Author(s):  
Richard McGonigle ◽  
Wei Boon Yap ◽  
Swee Tin Ong ◽  
Derek Gatherer ◽  
Saskia E. Bakker ◽  
...  

Vaccine ◽  
2020 ◽  
Vol 38 (16) ◽  
pp. 3201-3209
Author(s):  
Sebastian Aston-Deaville ◽  
Emil Carlsson ◽  
Muhammad Saleem ◽  
Angela Thistlethwaite ◽  
Hannah Chan ◽  
...  

2015 ◽  
Vol 57 (11-12) ◽  
pp. 1038-1049 ◽  
Author(s):  
Andris Dishlers ◽  
Dace Skrastina ◽  
Regina Renhofa ◽  
Ivars Petrovskis ◽  
Velta Ose ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document